Evidence map›Paper›PMID 22711905›Full record

ArticleThe Journal of infectious diseases2012

Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care.

Jason R Andrews, Robin Wood, Linda-Gail Bekker, Keren Middelkoop, Rochelle P Walensky

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Observational
  15. Article
  16. Article
  17. Bringing population mobility into focus to achieve HIV prevention goals.Journal of the International AIDS Society · 2018
    Article
  18. Article
  19. Article
  20. The missing 27.AIDS (London, England) · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jason R AndrewsDivision of Infectious Diseases, Massachusetts General Hospital, 50 Staniford St, 9th Fl, Boston, MA 02114, USA. jandrews6@partners.org
Robin Wood
Linda-Gail Bekker
Keren Middelkoop
Rochelle P Walensky

Funding

AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI LIPSITCH, MARC · 2009 to 2018
$26.4M
Optimizing HIV Care in Less Developed CountriesR01AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Emily Parker Hyle · 2004 to 2026
$21.5M
Novel Methods to Inform HIV/TB Clinical Trial DevelopmentR01AI093269 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI REDDY, KRISHNA P · 2011 to 2024
$6.8M
Modeling the Impact of HIV Prevention InterventionsR01MH087328 · NIMH · HARVARD SCHOOL OF PUBLIC HEALTH · PI SEAGE, GEORGE R · 2010 to 2013
$2.7M
NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI058736NIAID NIH HHS R01 AI093269NIAID NIH HHS U01 AI068636NIGMS NIH HHS U54 GM088558NIMH NIH HHS R01 MH087328NIMH NIH HHS R01 MH087328-02
6 · The paper itself

Abstract

backgroundRecent mathematical models suggested that frequent human immunodeficiency virus (HIV) testing with immediate initiation of antiretroviral therapy (ART) to individuals with a positive test result could profoundly curb transmission. The debate about ART as prevention has focused largely on parameter values. We aimed to evaluate structural assumptions regarding linkage to care and population mobility, which have received less attention.

methodsWe modified the linkage structure of published models of ART as prevention, such that individuals who decline initial testing or treatment do not link to care until late-stage HIV infection. We then added population mobility to the models. We populated the models with demographic, clinical, immigration, emigration, and linkage data from a South African township.

resultsIn the refined linkage model, elimination of HIV transmission (defined as an incidence of <0.1%) did not occur by 30 years, even with optimistic assumptions about the linkage rate. Across a wide range of estimates, models were more sensitive to structural assumptions about linkage than to parameter values. Incorporating population mobility further attenuated the reduction in incidence conferred by ART as prevention.

conclusionsLinkage to care and population mobility are critical features of ART-as-prevention models. Clinical trials should incorporate relevant data on linkage to care and migration to evaluate the impact of this strategy.

Indexed as

AdolescentAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveDisease Transmission, InfectiousEmigration and ImmigrationHealth Services AccessibilityHIV InfectionsHumansModels, TheoreticalPatient Acceptance of Health CareSouth AfricaAnti-HIV Agents

Identifiers

PMID22711905
PMCPMC3491737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.